Formulation Development

LIVE BIOTHERAPEUTIC PRODUCTS - Not All Microbiome Approaches Are Created Equal

Duncan Peyton says in comparison with other therapeutic classes, such as antibodies or gene therapy, the progress that has been made with LBPs to date has been rapid, and for the field to maintain this rate of progress and to establish LBPs as a mainstay in the treatment of patients across a variety of diseases, a number of key questions need to be addressed.

EXCLUSIVE ONLINE CONTENT

WEBINARS

WHITE PAPERS